trial · primary record
AZD0305
Multiple Myeloma
| Phase | Phase 1, Phase 2 |
|---|---|
| Status | RECRUITING |
| Sponsor | Unknown |
| Enrolment | 226 |
| Primary completion | 2028-01-24 |
| Primary endpoint | Occurrence of dose-limiting toxicity (DLT), as defined in the protocol (Phase Ia dose escalation only) |
| Registry ID | NCT06106945 |
Provenance
- Source: ClinicalTrials.gov
- Fetched at: 2026-10-30T14:40:24.036Z
- Licence class: attribution-required
- Verdict: primary-source
- Entity id: NCT06106945
This record is rendered from the AEaH spine. If the source is unreachable the page is not generated.